Exagen Q2 2026: record revenue $19.9M (+16% YoY), net loss narrowed, guidance raised

EXAGEN INC.

Revenue $19.9M, up 16% YoY; net loss $3.2M vs $4.4M in Q2 2025, improved 28%.
Adjusted EBITDA loss narrowed to $0.1M from $1.7M; operating loss $1.7M vs $2.6M.
AVISE CTD test volume +11% YoY; trailing 12-month ASP $446, up $18 (+4%).
Full-year 2026 revenue guidance raised to $72-75M from prior $70-73M.
Cash $24.6M; published study showing AVISE Lupus identified ~25% of SLE patients missed by conventional markers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.